Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,416.00+0.10%ETH$2,442.29+0.95%GOLD$4,397.70-0.05%OIL$100.86-1.03%
Smart Investors Daily
IX

NASDAQ · IXHL

Incannex Healthcare Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$3.80

Down-$0.21 (-5.53%)

Updated Sep 18, 2026, 1:00 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.08M
P/E ratio
-0.24
Dividend yield
0.00%
52-week range
$2.49 – $6.46
Volume
382.18K
Avg. volume
27.92M

Price performance

IXHL price history

1M range · 0 trading sessions · Daily adjusted prices

IXHL does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest IXHL news

The latest Smart Investors Daily articles mentioning IXHL.

Stock researchCompany · Overview

IXHL research

Overview

Company profile and research snapshot.

Company profile

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
IXHL recent ratings
DateFirmRatingTarget
Jun 8, 2026Alliance Global PartnersBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apneaU.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040Approximately $70 million in cash and no debt, including more than A$11.2 million in non-dilutive capital received during 2026 NEW YORK and MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biop

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By